Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chuikyo Approves Pfizer’s Selzentry And Janssen Pharma’s Intelence For NHI Listing

This article was originally published in PharmAsia News

Executive Summary

Japan's Central Medical Social Insurance Association (Chuikyo) approved Jan. 14 and listed the price for two HIV antiviral drugs, Pfizer's Selzentry (maraviroc) and Janssen Pharma's Intelence (etravirine). For maraviroc, indicated to treat patients with CCR5-tropic HIV-1 detectable who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents, Chuikyo set the price of ¥2,278.80 per tablet. Designated as an orphan drug, etravirine 100mg was set at ¥619.8 per tablet and a one-day dosage expense of ¥2,478.20. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069834

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel